Menu
ncarol.com
  • Home
  • Business
  • Finance
  • Financial
  • Music
  • Health
  • Loans
  • Boat Dealers
  • Nyse
ncarol.com

Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
ncarol.com/10280466

Trending...
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
  • Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
Laboratory Testing for Product Validation BSR Labs Juventix PRP Study Table Juventix Packaging With Tubes Juventix Regenerative Medical, LLC
TAMPA, Fla. - ncarol.com -- Juventix Regenerative Medical, a leader in regenerative medicine solutions, proudly announces that its Platelet-Rich Plasma (PRP) technology has been featured in a groundbreaking university-published research study. The study, titled "Platelet-Rich Plasma for Rheumatoid Arthritis: A Case Series", published in the peer-reviewed journal Cureus, underscores the efficacy of Juventix PRP in managing rheumatoid arthritis, showcasing its transformative potential in clinical applications.

The study explores the use of PRP to address inflammation and improve outcomes in rheumatoid arthritis patients, with findings demonstrating measurable benefits attributed to Juventix PRP's advanced process. The research highlights the role of PRP in promoting tissue repair and reducing joint pain, offering a promising non-surgical alternative for patients seeking regenerative therapies.

Scientific Validation Backed by Laboratory Studies
Juventix PRP's inclusion in this research aligns with findings from extensive laboratory evaluations conducted by BioSciences Research Associates (2020) and Biofyl Scientific Research (2023). Key results include:
  • 84% platelet recovery, significantly enhancing platelet-derived growth factor (PDGF) concentrations.
  • 10x increase in PDGF levels, with treated PRP reaching 10,844 pg/mL compared to 1,536 pg/mL in untreated samples.
  • Minimal contamination of red and white blood cells, ensuring safety and reducing inflammatory risks.
  • Optimized pH of 7.5, creating an ideal environment for platelet activation and growth factor release.
  • Innovative activation methods, including photoactivation and bio-incubation, transforming PRP into PRF for versatile clinical applications.
"The inclusion of Juventix PRP in a peer-reviewed study underscores our commitment to delivering scientifically validated, high-quality regenerative solutions," said Lance Liberti, CEO of Juventix Regenerative Medical. "Our focus on innovation ensures practitioners can trust Juventix PRP for consistent, superior patient outcomes."

More on ncarol.com
  • Cyntexa Outlines a Principles-first Approach to Modern Enterprise Transformation
  • Kickstarter And Creator Camp Partner To Support A New Era Of Creator-led Independent Film
  • Top 66 People-Centric Leaders of 2025 Prove Taking Care of People Is Taking Care of Business
  • Kliemann Brothers Announces 2025 Furnace Giveaway Winners
  • Daniel Kaufman Launches a Vertically Integrated Real Estate and Investment Platform

Special Offer for Medical Practitioners
To introduce clinicians to its cutting-edge PRP systems, Juventix is offering a sample PRP kit for only $20. This limited-time opportunity enables practitioners to experience the proven quality of Juventix PRP firsthand.
• Email: hello@juventix.com with the subject line "SAMPLE"
• Visit: https://juventix.com/sample-page/

About Juventix Regenerative Medical, LLC
Founded in 2017 by Lance Liberti, Juventix Regenerative Medical has been a pioneer in non-surgical regenerative solutions, including FDA-cleared PRP kits. The company offers comprehensive products such as centrifuges, LED activators, and bio-incubators to support superior PRP preparation. Juventix also collaborates with prestigious organizations, including the University of South Florida (USF) Health Center for Advanced Medical Learning and Simulation (CAMLS), to host advanced clinical training symposiums.

For more information, visit www.Juventix.com or contact:
📞 (866) 693-4777

More on ncarol.com
  • Long Long Tales: Bilingual Cartoon Series on Youtube Celebrating Chinese New Year
  • MAX Illumination Redefines Cabinet Displays with New Edge-Lit LED Technology
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care
  • FeedSocially - Post Once, Publish Everywhere
  • James D. Harding Promoted to Century Fasteners Corp. – Managing Director

✉️ Email:
hello@juventix.com
Restore, Revive, Regenerate – Juventix Regenerative Medical.

Media Contact
Lance Liberti
***@juventix.com
866-693-4777


Source: Juventix Regenerative Medical, LLC

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
  • Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
  • Boston Corporate Coach™ Sets Global Standard for Executive Chauffeur Services Across 680 Cities
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
  • Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee
  • 14 Years of Sparking Curiosity in Out-of-School Time: From Empowering Gen Z to Nurturing Gen Alpha
  • Secondesk Launches Powerful AI Tutor That Speaks 20+ Languages
  • Automation, innovation in healthcare processes featured at international conference in Atlanta
  • A High-Velocity Growth Story Emerges in Marine and Luxury Markets
  • $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway
  • 1300+ Small Business Leaders Sign Letter to Congress Urging Prompt Action to Protect US Innovation
  • Peernovation 365 is Now Available
  • Snap-a-Box Brings Texas' First Robot-Cooked Chinese Takeout to Katy–Fulshear
  • UK Financial Ltd Makes History as MayaCat (SMCAT) Becomes the World's First Exchange-Traded ERC-3643 Security Token
  • Narcissist Apocalypse Marks 7 Years as a Leading Narcissistic Abuse Podcast
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • CryptaBox Introduces a Hardware Crypto Cold Storage Wallet
  • YWWSDC Launches AI-Native Digital Asset Infrastructure, Merging Technical Innovation with US-Standard Compliance
  • High-End Exterior House Painting in Boulder, Colorado
  • Simpson and Reed Co-Founders Shardé Simpson, Esq. and Ciara Reed, Esq. Launch "Hello Wilma,"
_catLbl0 _catLbl1

Popular on ncarol.com

  • VDG Virtuoso Emerges as a New-Model Independent Industry Figure Blending Artist, Executive, and Infrastructure Builder - 119
  • Walmart $WMT and COSTCO.COM $COST Distribution as SonicShieldX™ Platform Sets the Stage for Accelerated Growth in 2026: AXIL Brands (N Y S E: AXIL) - 115
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations - 111
  • $26 Billion Global Market by 2035 for Digital Assets Opens Major Potential for Currency Tech Company with ATM Expansion and Deployment Plans Underway - 106
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow - 103
  • UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
  • David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
  • Lick Personal Oils Introduces the Ultimate Valentine's Day Gift Collection for Romantic, Thoughtful Gifting
  • UK Financial Ltd Executes Compliance Tasks Ahead Of First-Ever ERC-3643 Exchange-Traded Token, SMCAT & Sets Date For Online Investor Governance Vote
  • Phinge Founder & CEO Robert DeMaio Ranked #1 Globally on Crunchbase, Continues to Convert Previous Debt Owed to Him by Phinge into Convertible Notes

Similar on ncarol.com

  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care
  • Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
  • CCHR White Paper Urges Government Crackdown on Troubled Teen and For-Profit Psychiatric Facilities
  • Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
  • Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
  • Automation, innovation in healthcare processes featured at international conference in Atlanta
  • 1300+ Small Business Leaders Sign Letter to Congress Urging Prompt Action to Protect US Innovation
  • High-Impact Mental Health Platform Approaching a Defining Regulatory Moment: Eclipsing 70,000 Patients on Real World Use of Ketamine: N ASDAQ: NRXP
  • Report Outlines Key Questions for Individuals Exploring Anxiety Treatment Options in Toronto
  • CCHR Says Mounting Evidence of Persistent Sexual Dysfunction From Antidepressants Demands FDA Action
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute